key: cord-0823923-e49rdu76 authors: Lavine, J. S.; Bjornstad, O. N.; Antia, R. title: Immunological characteristics govern the changing severity of COVID-19 during the transition to endemicity date: 2020-09-05 journal: nan DOI: 10.1101/2020.09.03.20187856 sha: 35c4cedca0c1b55dab91de4e7c85b841d4de297f doc_id: 823923 cord_uid: e49rdu76 As prospects for eradicating CoV-2 dwindle, we are faced with the question of how the severity of CoV-2 disease may change in the years ahead. Will CoV-2 continue to be a pathogenic scourge that, like smallpox or measles, can be tamed only by ongoing vaccination, or will it join the ranks of mild endemic human coronaviruses (HCoVs)? Our analysis of immunological and epidemiological data on HCoVs shows that infection-blocking immunity wanes rapidly, but disease-reducing immunity is long-lived. We estimate the relevant parameters and incorporate them into a new epidemiological model framework which separates these different components of immunity. Our model recapitulates both the current severity of CoV-2 and the relatively benign nature of HCoVs; suggesting that once the endemic phase is reached, CoV-2 may be no more virulent than the common cold. The benign outcome at the endemic phase is contingent on the virus causing primary infections in children. We predict a very different outcome were a CoV like MERS (that causes severe disease in children) to become endemic. These results force us to re-evaluate control measures that rely on identifying and isolating symptomatic infections, and reconsider ideas regarding herd immunity and the use of immune individuals as shields to protect vulnerable groups. Emerging pathogens have been invading the human host niche through history (such as 27 smallpox emerging from an ancestral animal pox virus and rinderpest evolving to measles) 28 to kill a substantial fraction of all people born. Recent decades have seen multiple chal-29 lenges that cause severe viral disease, such as SARS, MERS, Hendra, Nipha and Ebola. 30 Fortunately, all these are examples of emerging diseases that were locally contained. When 31 containment is not successful, as is likely for the novel betacoronavirus SARS CoV-2 (CoV- 32 2) [1, 2] , we need to understand and plan for the transition to endemicity and continued 33 circulation, with possible changes in disease severity due to virus evolution and build-up 34 of host immunity and resistance. 35 COVID-19 is an emerging infectious disease caused by CoV-2 that has a high basic re-36 productive number (R 0 ) and significant transmission during the asymptomatic phase, both 37 of which make it hard to control [3] . However, CoV-2 is not the first coronavirus identified 38 with human-to-human transmission: there are six other coronaviruses with known human 39 chains of transmission, and these can provide clues to future scenarios for the current pan-40 demic. There are four human coronaviruses (HCoVs) that circulate endemically across the 41 globe; they cause only mild symptoms and are not a significant public health burden [4] . 42 Another two HCoV strains, SARS CoV-1 and MERS, emerged in the past few decades 43 and had higher case fatality ratios (CFRs) than COVID-19 but were contained and never 44 spread widely [5, 6] . 45 We propose a model to explore the potential changes in both transmission and disease 46 severity of emerging HCoVs through the transition to endemicity. We focus on CoV-2, and 47 discuss how the conclusions would differ for emerging coronaviruses more akin to SARS and 48 MERS. Our hypothesis is that all HCoVs elicit immunity with similar characteristics, and 49 the current acute public health problem is a consequence of epidemic emergence into an 50 immunologically naive population in which frail age-groups have no previous exposure. We 51 use our estimates of immunological and epidemiological parameters for endemic HCoVs to 52 develop a quantitative transmission model and incorporate the age-dependence of severity 53 from primary infections of emerging HCoVs. Our model explicitly considers three separate 54 measures of the efficacy of immunity which can wane at different rates. These novel features 55 allow us new insights into potential changes in both transmission and disease severity in 56 the coming years (Fig 1) . 57 Building on ideas from the vaccine modeling literature, immunity may be thought to 58 provide protection in three ways [7] . In its most robust form, "sterilizing" immunity can 59 prevent a pathogen from replicating, thereby rendering the host refractory to reinfection. 60 We term this property immune efficacy with respect to susceptibility, IE S . If immunity 61 does not prevent reinfection, it may still attenuate the pathology due to reinfection (IE P ) 62 and/or reduce transmissibility or infectiousness (IE I ). Experimental re-exposure studies 63 on endemic HCoVs provide evidence that the three IE's do not wane at the same rate 64 [8, 9] . Callow's experimental study [8] shows that reinfection is possible within one year (relatively short IE S ); however, upon reinfection symptoms are mild (high IE P ) and the 66 virus is cleared more quickly (moderate IE I ). Details the derivation of the model are in SI 67 section 2. 68 3 Results 69 3.1 Endemic dynamics and age structure 70 We use available data on age-specific seroprevalence of IgM (acute response) and IgG 71 (long-term memory) against the four circulating HCoVs to estimate parameter ranges for 72 transmission and waning of immunity [10] . The data are plotted and further analyzed infected so early in life -younger even than measles in the pre-vaccine era -there must be 78 a very high attack rate, too high to be due only to transmission from primary infections. 79 Steady state analysis of the model shows how this attack rate arises from a combination 80 of high transmissibility from primary infections (i.e., high R 0 ) and waning of sterilizing 81 immunity and significant transmission from reinfections in older individuals. The rapid 82 waning of sterilizing immunity is also documented in experimental HCoV infections of 83 humans which showed that reinfection is possible one year after an earlier infection, albeit 84 with milder symptoms (IE P ) and a shorter duration (IE I ) [11] . Figure 2B shows the 85 plausible combinations of waning immunity and transmission from reinfected individuals 86 that is required to produce the MAPI observed in Figure 2A . Table 1 shows the ranges of 87 the parameters used in our simulations. At the beginning of an outbreak, the age distribution of cases mirrors that of the population 90 ( Fig 3A) . Once the demographics of infection reaches a steady state, however primary 91 cases occur almost entirely in babies and young children, who in the case of COVID-92 19, experience a low CFR. Reinfections in older individuals are predicted to be common 93 and contribute to transmission, but in this steady-state population, older individuals, who 94 would be at risk for severe disease from a primary infection, have acquired disease-reducing 95 immunity following infection during childhood. The overall CFR for CoV-2 is predicted to drop dramatically, eventually falling below to endemicity depends on both transmission (R 0 ) and loss of immunity (ω and ρ) ( Fig 3B 100 and SI Fig 1) . 101 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 5, 2020. . https://doi.org/10.1101/2020.09.03.20187856 doi: medRxiv preprint In the absence of vaccination or treatment, high transmission is predicted to lead to 102 a high case load and death rate in the initial epidemic phase during the first few years 103 following emergence (Fig 3 and SI Figs 3 & 4) . The total number of deaths is largely 104 independent of R 0 (see SI Fig 6) . Slowing down the epidemic through social distancing 105 measures that lower R 0 flattens the curve, thus delaying infections and preventing the 106 majority of deaths from happening early on, affording critical time for the development of 107 an effective vaccine or treatment. However, as the time scales of disease spread and waning 108 of immunity meet, transmission from reinfected individuals (likely asymptomatic or mild) 109 to the vulnerable is predicted to increasingly drive excess deaths (SI Fig 5) . Our prediction of mild CoV-2-associated pathology in the long run stems from the 111 low CFR for primary infections in young children. Were a more pathogenic emerging 112 coronavirus to become endemic, for example one with an age-dependent CFR similar to 113 CoV-1, we still expect a low disease burden in the long run (Fig 4) . However, data suggest 114 not all emerging HCoVs follow this optimistic pattern; the overall CFR of an endemic 115 MERS-like virus would increase during the transition to endemicity because disease severity 116 is high in children, the age group expected to experience the bulk of primary cases during 117 the endemic phase. The key result from our new model framework that explicitly recognizes that functional 120 immunity to reinfection, disease and shedding are different is that, in contrast with in-121 fections that are severe in childhood, CoV-2 could join the ranks of mild, cold-causing 122 endemic human coronaviruses in the long run. A critical prediction is that the severity of 123 emergent CoVs once they reach endemicity depends only on the severity of primary infec-124 tion in children (Fig 4) because all available evidence suggests immunity to HCoVs has 125 short IE S , moderate IE I but strong IE P such that childhood infection provides protection 126 from pathology upon reinfection in adulthood. Strain-specific virulence factors, such as 127 the shared cellular receptor, ACE-2, to which CoV-1, CoV-2 and the endemic strain NL63 128 all bind [18, 19, 20, 21] , may affect the CFR during the emergence phase but have little 129 impact on the severity of disease in the endemic phase. Because the four endemic HCoVs 130 have been globally circulating for a long time and almost everyone is infected at a young 131 age, we cannot ascertain how much pathology would result from a primary case of any of 132 these in an elderly person. The key insights come from how our model explicitly incorporates different components 134 of immunological protection with respect to susceptibility, pathology and infectivity (IE S , 135 IE P and IE I ) and their different rates of waning. In our analysis we hypothesized that the 136 rates for CoV-2 are comparable to endemic HCoVs. Testing this assumption for CoV-2 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 5, 2020. . https://doi.org/10.1101/2020.09.03.20187856 doi: medRxiv preprint primary, secondary and subsequent infections of individuals. In our projections, we make 140 the simplifying assumption that immune memory following a single infection generates 141 protection from pathology (high IE P ). However, we expect our results to be robust to a Table 2 . The findings presented 161 here suggest that using symptoms as a surveillance tool to curb the virus's spread will 162 become more difficult, as milder reinfections increasingly contribute to chains of transmis-163 sion and population level attack rates. In addition, infection or vaccination may protect 164 against disease but not provide the type of transmission-blocking immunity that allows for 165 shielding [24] or the generation of long-term herd immunity [2] . 166 From an ecological and evolutionary perspective, our study opens the door to questions 167 regarding the within-host and between-host dynamics of human immunity and pathogen CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 5, 2020. incorporates the following features of natural HCoV infections: recovered individuals (R 1 ) have sterilizing immunity (high IE S ) immediately after infection, and this immunity wanes over time at rate ω; individuals whose sterilizing immunity has waned (R 2 ) can become reinfected (I 2 ), albeit with mild symptoms (IE P is high) and reduced transmission to others (compared with transmission from primary infections, i.e., ρ ≤ 1). We use an age-structured version of this model with parameters for demography of the US population in our simulations of transient dynamics. See SI Sec 2 for equations and details. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. Table 1 (i.e., R 0 = 2 and R 0 = 10).) 7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. Simulations from an extension of the model presented in Fig 1 that includes age structure. Demographic characteristics such as the population's age distribution, birth, and age-specific death rates are taken from the USA, and seasonality is incorporated via a sinusoidal forcing function (see SI Sec 2.2). Panel A. The black line representing the number of infections per day shows an initial peak and subsequent transition to endemic dynamics with much lower numbers of infections (with the endemic dynamics from years 5 to 10 shown in the inset). The three plots in A show that a higher R 0 results in a larger and faster initial epidemic and more rapid transition to endemic dynamics. We also show (on the same plot) how the proportion of primary cases in different age groups changes over time (plotted in different colors), and how the transition from epidemic to endemic dynamics results in primary cases being restricted to the lower age groups. Parameters for simulations: ω = 1 and ρ = 0.7. In Panel B, we plot how long it takes for the average CFR (calculated as a 6 month moving average) to fall to 0.001, the CFR associated with seasonal influenza. Grey areas represent simulations where the CFR did not reach 0.001 within ten years. We see that the time taken for the CFR to decline to that of influenza decreases as the transmissibility (R 0 ) increases and the duration of sterilizing immunity becomes shorter. Results are shown for ρ = 0.7. See SI Sec 2.3 and SI Figs 3-5 for sensitivity analyses and model specifications. 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. A B R 0 Figure 4 : The age dependence of the CFR determines how the overall CFR changes during the transition from epidemic to endemic dynamics for emerging CoVs. Panel A shows the age dependence of the CFRs for the three emerging CoVs. CoV-1 and CoV-2 have a J shaped profile, with a monotonic increase in CFR with age. In contrast, the age dependence of the CFR for MERS is U shaped, with high mortality in the younger as well as older age groups. Details of the statistical smoothing are described in SI Sec 5. Panel B shows how the overall CFR (computed from modelpredicted infections in each age group multiplied by the age-specific CFRs for the different CoVs) changes with the transition from epidemic to endemic dynamics. We see the overall CFR declines as CoV-2 transitions to endemicity, and we predict a similar trend should a CoV-1 (SARS)-like viurs spread widely. In contrast, the model predicts the CFR for a MERS-like virus would increase with time; this increase is a consequence of the shape of the age-dependence of the CFR for MERS. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. . Waning transmission-reducing immunity (IE S and IE I ) with long-lasting protection against severe disease (IE P ) leads to an increase in asymptomatic reinfections. Identifying and quarantining index cases becomes more difficult. Localized outbreaks are more difficult to control, particularly in places with a large first wave of infections (SI Sec 4). Widespread / universal testing regardless of symptoms Given that prior infection and the presence of CoV-2-specific antibodies may indicate stronger IE P than IE S or IE I , this strategy is a double-edged sword. Those with antibodies may be less likely than those without to get infected and transmit, but they may also be more likely to have an asymptomatic infection that can spread without their knowledge of it. The chance of this scenario increases with time since infection. It may not be possible to rely on seropositive individuals as caregivers to shield the elderly and vulnerable as has been proposed [24], but they are a good choice for frontline workers or those caring for COVID patients because they are less likely to have severe pathology following reinfection. • Identify immune surrogates of IE S , IE P and IE I . • Time stamps on immunity passports. Both social distancing and everyday use of personal protective equipment (PPE) reduce the spread of infection (i.e., reduce R 0 ) regardless of symptoms and therefore their efficacy does not depend on detecting symptoms. Increase PPE use to maintain local R 0 < 1 with businesses as open as possible. Vaccination Vaccination, like natural infection, may not provide long-lasting transmissionblocking immunity. Consequently herd immunity will not be achieved, and the traditional strategy of vaccinating high-contact rate groups will not provide long-term protection to the rest of the population. Instead, vaccination should target those most vulnerable to severe disease (i.e., the elderly) to reduce the overall CFR during the transition to endemicity and essential workers most frequently exposed (i.e., front-line workers). • Target vaccination toward the elderly, frontline workers, and other vulnerable populations. • Generate a 'smart vaccine' that produces better-thannatural, transmissionblocking immunity. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. 12 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. . Immunological characteristics will govern changing severity of COVID-19 during the likely transition to endemicity: Supplement Jennie Lavine, Ottar Bjornstad, Rustom Antia August 21, 2020 We used data from a 2013 study [1] on the seroprevalence of IgG and IgM antibodies against the Spike (S) protein of the four endemic HCoV strains in a cross-section of the population in Beijing, none of whom exhibited symptoms. A striking feature of these data is that IgM titers are undetectable in all of the more than 140 subjects ages 15 yr and older. This observation combined with general knowledge of the the IgM response [2] suggests that S-specific IgM is only elicited during primary infection. Additionally, IgM titers decay quickly, which makes IgM seropositivity a useful marker of recent primary infection. We calculate error bars on the seroprevalence for both IgM and IgG and estimate the mean age of primary infection (MAPI) for each of the four strains from the IgM data. We assume the data for both IgM and IgG stem from a binomial process where the probability of seropositivity in age group j is p j , estimated bŷ p j and the sample size for each age group is N j . The 95% confidence interval around the mean proportion seropositive for each age group is then We further estimate the MAPI using only the IgM data (we assume that the cases are uniformly distributed within each age group -a more accurate estimate could be obtained from the raw data with smaller age bins; unfortunately we were unable to gain access to it). For each HCoV strain, s, we create a vector, A s with length L containing the ages ages of IgM seropositivity (using the midpoints of each age range). We assume this is a reasonable reflection of ages of first infection, as IgM titers increase only during primary infection and decay in a matter of weeks [3] . The 95% CI for the MAPI for each strain, s, is therefore estimated by We derived the model presented in Fig 1 by combining three key sources of information: (1) classic SIRS disease transmission models, (2) separated functional immune efficacies (IE's, [4] ), and (3) a human reinfection experiment with HCoV 229e in fifteen healthy adult volunteers [5] . In aforementioned reinfection experiment, all subjects had serum specific antibodies at the start, suggesting that participants had already experienced a primary infection. The first experimental exposure resulted in viral replication and a boosting of IgG titers in ten of the fifteen participants; the group that supported viral replication had lower serum specific IgG, IgA and nasal IgA levels prior to exposure and shed virus for on average 5.6 days; eight out of ten had cold symptoms. Antibody titers increased significantly approximately a week after infection and then slowly decayed over the course of the next year. Among the five participants who did not get infected following exposure at the beginning of the trial, antibody titers remained relatively constant following exposure; however their IgG titers did drop significantly by the end of the year. 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. . https://doi.org/10.1101/2020.09.03.20187856 doi: medRxiv preprint One year after the initial exposure, fourteen of the fifteen participants were re-exposed. All five who had not sustained an infection the first time became infected (their IE S waned) and one developed cold symptoms (IE P was still strong for four of the five). Six of the nine who had supported viral replication a year earlier sustained an infection following exposure the second time (their IE S waned within the span of year) but none developed cold symptoms (they retained IE P ); the other three did not become infected following exposure. Among all who got infected at the second time point, the mean duration of viral shedding was only 2.0 days, suggesting that IE I had not waned completely. Based on these observations, the following are the basic equations that correspond to Fig 1. dS The above equations are used for steady state analysis of the predicted mean ages of primary infection (MAPIs). The model-predicted MAPI for a given set of parameters is calculated as the waiting time from birth to first infection according to the following equation: whereÎ i is the equilibrium proportion of the population in class I i . The equilibrium values are calculated by first running a short (100 iterations = 1/10 yr) numerical simulation using a wrapper for the R function lsoda and then using the final values as estimates to start the Newton-Raphson method to find equilibria as implemented in the R package rootSolve, function stode. We additionally calculate the proportion of cases caused by reinfections as follows: In addition to the results shown in the main text for R 0 = 5, we here show figures parallel to Fig 3b for R 0 = 2 and R 0 = 10 (SI Fig 1) . To incorporate seasonality with a peak in early January (modeling on influenza and seasonal coronaviruses) and the introduction of the virus in early March (as was approximately observed with CoV-2 in the US), cases are introduced at t=0 and we allow β to fluctuate annually according to β 0 is the mean value of β, and β 1 is the amplitude of the sin wave. All results shown here use β 1 = 0.2 (SI Figs 3-6 and Fig 3 in the main text) . Additionally, to incorporate the age-specific case fatality rates, death rates (δ), and the current age distribution of the US population, we separate each immune state, X, into nine age classes X j with 10-yr widths for the first eight. The aging rates correspond to the width of the age classes; the death rates and age distribution are taken from US data. This yields the following equations: CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. where N (t) = J j=1 X t is the total population size at time t. The birth rate, µ, is a vector of length nine, containing the overall population birthrate (based on demographic data) followed by zeros for all subsequent age classes (i.e., people are only born into the youngest age class). The age-specific death rates, δ j , are fixed at values estimated from demographic data. The aging rates, λ j , are contained in a vector of length ten: (0, 0.1, 0.1, 0.1, 0.1, 0.1, 0.1, 0.1, 0.04, 0) . We fix γ at 365 9 corresponding to an infectious period that lasts on average nine days. β 0 is calculated according to β 0 = R 0 (γ + µ). We consider a range of values of R 0 (2-10), ω (0-2), and ρ (0-1). The age-specific death rates were inferred from CDC data Health Statistics [6] , and were calculated as follows: death_rate_age<-as.data.frame(cbind (age=seq(25,95,by=10) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. . https://doi.org/10.1101/2020.09.03.20187856 doi: medRxiv preprint family=gaussian(link='log')) ) pred.ages<-seq(5,85,length=9) pred_death_rate<-exp(predict(death_rate.glm, data.frame (age=seq(0,100,by=0.5) ))) mod.pred<-round(exp(predict(death_rate.glm, data.frame(age=pred.ages))),5) print(mod.pred) The ages used in the model prediction for death rates were the midpoints of the age classes (e.g. 5, 15, 25yr, etc). We used the death rate for 85 yr olds as the highest death rate. The initial conditions were set so the population was distributed into the nine susceptible classes according to the age distribution of the US population [7] . One infected individuals was seeded into each age group's I 1 class. The following steps were used to calculate the number of daily infections and 6-month moving average case fatality rate (CFR): 1. Numerically integrate equations with chosen parameters and initial conditions as described above using the R function lsoda with a time step of one day (1/365 yr). 2. Calculate the probability of staying in I 1 for a timestep of one day given that you're already there. In the simplest version of the model we consider here, this can be calculated using the cumulative distribution function, F : P (stay in I in time step∆t) = 1 − F (γ, ∆t) (16) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. . 5. For every 6-month window, calculate the overall CFR beginning six months into the pandemic The key result that the overall CFR drops to something akin to seasonal influenza (0.001), is robust across a wide range of values for R 0 , ω and ρ for COVID-like CFRs. We additionally show results for simulations with different initial conditions, in which 2000 infections were seeded into each age groups approximating the situation when the pandemic was under control in the U.S. (i.e., there had been already been many infections and R 0 was close to 1). The CFR evolves very similarly to the case where only nine cases are introduced. Additionally, we see that keeping R 0 below a threshold value (in these simulations approximately 2, e.g., by social distancing and the use of Personal Protective Equipment) allows us to stop the majority of deaths from happening early on, buying time for the development of an effective vaccine and/or treatment (SI Fig 5) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. However, as we slow down the epidemic by decreasing R 0 , the time scales of disease spread and immune waning meet, and reinfections increasingly drive excess deaths, and the total number of infection-induced deaths within the first decade after emergence is very similar regardless of how fast the infection is spreading (SI Fig 6) . 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. We estimate the duration of sterilizing immunity based on Callow et al. [5] , in which six out of nine people who got infected at the start of the experiment were susceptible to reinfection one year later. We can calculate the mean of ω given this for exponentially distributed waning times setting the CDF equal to 2/3. Given this, the estimate for ω is 1.099 and the mean waiting time is 1/ω = 0.91 yr. We can also find the average duration of immunity for normally distributed waning times. We assume that the variance is the same as for the exponential model, 1 λ 2 and the standard deviation is 1 λ . Here, we find the estimate for the mean of ω to be 0.61/yr, so the mean waiting time is 1 0.61 = 1.64yr. To better understand how waning of immunity impacts symptom-based quarantining in the first few years after disease emergence, we consider the following three phases. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. The initial epidemic, before control measures are introduced, burns through a proportion of the population, p 1 . At some point, let's call it t 0 , we introduce highly effective quarantining, which breaks chains of transmission. Because the initial epidemic burns through the population quickly, we approximate the time of entry into R 1 as being uniform. Additionally, since chains of transmission are broken upon the introduction of effective quarantining and contact tracing, we assume no new cases arise after t 0 during Phase1. Therefore at t 0 (or shortly after): There is a time period during which the occasional immigrant case enters, but no chains of transmission start. Even if the immigrant with a primary or secondary infection infects a Susceptible person before being quarantined, that I 1 is immediately quarantined and does not infect others. If an R 2 person is infected, they are not quarantined but neither can they start a chain of transmission because any infection to S results in quarantine, and a transmission chain all among secondary (or later) cases will not happen because R E = R 2 ρβ 0 /(γ + µ) < 1. During this time period, people who have recovered from a primary infection are losing their immunity. During this phase: There is a threshold value of R 2 , let's call it R * 2 , above which an immigrant case can lead to an outbreak of asymptomatic secondary infections, which acts as a reservoir for symptomatic primary infections. This 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. occurs even in the presence of a strong quarantining program for symptomatic primary cases. If R * 2 > p 1 , quarantining can continue working indefinitely. However, if R * 2 < p 1 , immune waning will lead to a sufficient build up of secondary susceptibles (in R 2 ) to sustain an outbreak. In this scenario, the 'safe time' during which strong quarantining of primary cases can prevent outbreaks is influenced by: how fast immunity wanes (ω), how transmissible secondary cases are (ρβ 0 ) and the proportion of the population that was infected in the initial outbreak (p 1 ). During this phase: R 2 fluctuates as transmission occurs. Here, we show results for the window of safety during which strict quarantining of primary cases will prevent an immigrant infection from leading to an outbreak for R 0 = 6 and R 0 = 1.5 to mimic a high but reason-9 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2020. . https://doi.org/10.1101/2020.09.03.20187856 doi: medRxiv preprint Figure 10 : Phase 2 transmission able transmission rate and a rate that may be more commensurate with the current scenario given social distancing. For R 0 = 2 we see quar_thresh_R0 <-expression(1/(rho*propR2)) pars2<-expand.grid(R0=c(2,6), rho=seq(0.1,1,by=0.01), omega=seq(0.5,2,by=0.01), p.pulse=seq(0.3,0.7, by=0.1)) pars2$thresh.R2<-with(pars2, 1/(R0*rho)) pars2<-subset(pars2, thresh. R2